Frailty is associated with higher rates of morbidity, mortality, and failure to rescueafter major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal musclemass and strength. It is a key component of physical frailty and is associated withpoorer post-surgical outcomes due to decreased patient strength and vitality.
This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global
health crisis that was declared a national emergency by the US Federal Government on
March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver
transplant candidates.
Behavioral: COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC
This is a single-center, retrospective study that uses de-identified, anonymized patient
data. Data from 369 liver transplant candidates who underwent pre-transplant frailty
assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28,
2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the
pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020,
while the COVID period will consist of the dates between March 13, 2020 and February
28th, 2022.
Inclusion Criteria:
- Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC
Exclusion Criteria:
- Not a patient at Liver Institute at Methodist Dallas
Methodist Dallas Medical Center
Dallas, Texas, United States
Parvez Mantry, MD, Principal Investigator
Methodist Health System